MediWound's (MDWD) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of MediWound (NASDAQ:MDWD - Free Report) in a report released on Thursday morning,Benzinga reports. They currently have a $25.00 price objective on the biopharmaceutical company's stock. HC Wainwright also issued estimates for MediWound's FY2029 earnings at $2.45 EPS.

Separately, Craig Hallum began coverage on MediWound in a report on Friday, February 28th. They issued a "buy" rating and a $39.00 price objective for the company.

MediWound Trading Up 1.1 %

NASDAQ:MDWD traded up $0.18 during midday trading on Thursday, hitting $16.45. 51,846 shares of the company were exchanged, compared to its average volume of 90,000. MediWound has a fifty-two week low of $12.78 and a fifty-two week high of $24.00. The company has a market capitalization of $177.54 million, a PE ratio of -5.67 and a beta of 0.82. The company has a fifty day simple moving average of $18.13 and a 200 day simple moving average of $17.59.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.23. The business had revenue of $5.84 million for the quarter, compared to analysts' expectations of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter in the previous year, the firm earned ($0.19) earnings per share. As a group, equities research analysts expect that MediWound will post -2.66 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On MediWound

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. MetLife Investment Management LLC purchased a new stake in MediWound during the 3rd quarter valued at approximately $89,000. Investor AB purchased a new stake in shares of MediWound during the third quarter worth approximately $15,750,000. Point72 Asset Management L.P. acquired a new stake in shares of MediWound during the third quarter worth $212,000. State Street Corp grew its position in MediWound by 219.6% in the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company's stock valued at $1,197,000 after buying an additional 45,529 shares during the last quarter. Finally, Barclays PLC grew its position in MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock valued at $202,000 after buying an additional 8,449 shares during the last quarter. Hedge funds and other institutional investors own 46.83% of the company's stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.